Luis Villela

4PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 27, 2025
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose-response evidence.

Rafael Pichardo-Rodriguez, José M Vela-Ruiz, Luis Villela

|May 14, 2025
Comparing Hodgkin and Non-Hodgkin Lymphoma Mortality Between Latin America and the United States From 2008 to 2019: The Need of Regional-Based Lymphoma Registries.

Bryan Valcarcel, German Stemmelin, Sofia Rivarola

|Nov 19, 2024
Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory Hodgkin lymphoma.

Perla R Colunga-Pedraza, Héctor A Vaquera-Alfaro, Zulia Guzmán-Martínez

|Nov 03, 2022
Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)].

Luis Villela, María Torre-Viera, Henry Idrobo-Quintero

Pageof 1

Frequent Collaborators

2 joint publications

Luis Malpica

2 joint publications

Brady Beltran-Garate

2 joint publications

Maria-Alejandra Torres Viera

1 joint publications

Perla R Colunga-Pedraza